Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers.

被引：11
|
作者：
Hausman, Diana Felice
Hamilton, Erika Paige
Beeram, Muralidhar
Thimmarayappa, Jamuna
Ng, Gordon
Meric-Bernstam, Funda
机构：
[1] Zymeworks Biopharmaceut, Seattle, WA USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Brentwood, TN USA
[3] South Texas Accelerated Res Therapeut Ctr Canc Ca, San Antonio, TX USA
[4] Zymeworks Inc, Vancouver, BC, Canada
[5] Univ Texas MD Anderson Canc Ctr, Sheikh Khalifa Bin Zayed Nahyan Inst Personalized, Dept Invest Canc Therapeut, Dept Surg Oncol,Phase 1 Program, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.TPS215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS215
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers.
    Meric-Bernstam, Funda
    Beeram, Muralidhar
    Blum, Mariela A.
    Hausman, Diana Felice
    Infante, Jeffrey R.
    Patnaik, Amita
    Piha-Paul, Sarina Anne
    Rasco, Drew W.
    Rowse, Gerry
    Thimmarayappa, Jamuna
    Tolcher, Anthony W.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
    Meric-Bernstam, Funda
    Beeram, Murali
    Mayordomo, Jose Ignacio
    Hanna, Diana L.
    Ajani, Jaffer A.
    Murphy, Mariela A. Blum
    Murthy, Rashmi Krishna
    Piha-Paul, Sarina Anne
    Bauer, Todd Michael
    Bendell, Johanna C.
    El-Khoueiry, Anthony B.
    Lenz, Heinz-Josef
    Press, Michael F.
    Royer, Nels
    Hausman, Diana Felice
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Single agent activity of ZW25, a HER2-targeted bispecific antibody, in HER2-expressing gastroesophageal and other cancers
    Beeram, M.
    Hamilton, E.
    Hanna, D.
    Ajani, J.
    Murphy, M. Blum
    Bendell, J.
    El-Khoueiry, A.
    Hausman, D.
    Lenz, H. J.
    Patnaik, A.
    Press, M.
    Rowse, G.
    Thimmarayappa, J.
    Meric-Bernstam, F.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E17 - E17
  • [4] Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers
    Beeram, M.
    Hamilton, E.
    Murphy, M. Blum
    Hausman, D.
    Infante, J. R.
    Korn, R.
    Patnaik, A.
    Piha-Paul, S. A.
    Rasco, D.
    Rowse, G.
    Thimmarayappa, J.
    Tolcher, A.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] The bispecific antibody zanidatamab's (ZW25's) unique mechanisms of action and durable antitumor activity in HER2-expressing cancers.
    Weisser, Nina E.
    Wickman, Grant
    Abraham, Libin
    O'Toole, Jason
    Harbourne, Bryant
    Guedia, Joy
    Cheng, Chi Wing
    Chan, Peter
    Browman, Duncan
    Gold, Michael R.
    Josephson, Neil
    Dixit, Surjit
    Rowse, Gerry
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer
    Meric-Bernstam, Funda
    Chaves, Jorge
    Oh, Do-Youn
    Lee, Jeeyun
    Kang, Yoon-Koo
    Hamilton, Erika
    Mayordomo, Jose
    Cobleigh, Melody
    Vaklavas, Christos
    Elimova, Elena
    Ajani, Jaffer
    Rodon, Jordi
    Rowse, Gerry
    Gray, Todd
    Lai, Rose
    Hanna, Diana
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [7] Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours
    Oh, D-Y.
    Hamilton, E.
    Hanna, D.
    Beeram, M.
    Lee, K-W.
    Kang, Y-K.
    Chaves, J.
    Lee, J-Y.
    Goodwin, R.
    Vaklavas, C.
    Rha, S-Y.
    Elimova, E.
    Mayordomo, J.
    Ferrario, C.
    Cobleigh, M.
    Fortenberry, A.
    Rowse, G.
    Gray, T.
    Lai, R.
    Bernstam, F. Meric
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours
    Meric-Bernstam, F.
    Hanna, D.
    Beeram, M.
    Lee, K. -W.
    Kang, Y. -K.
    Chaves, J.
    Lee, J.
    Goodwin, R.
    Vaklavas, C.
    Oh, D. -Y.
    Rha, S. Y.
    Elimova, E.
    Mayordomo, J.
    Ferrario, C.
    Cobleigh, M. A.
    Fortenberry, A.
    Rowse, G.
    Gray, T.
    Lai, R.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 167 - +
  • [9] KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer
    Xu, Jianming
    Ying, Jieer
    Liu, Rongrui
    Wu, Jun
    Ye, Feng
    Xu, Nong
    Zhang, Yanqiao
    Zhao, Rusen
    Xiang, Xiaojun
    Wang, Jianhong
    Lin, Xiaoyan
    Xu, Huiting
    Gao, Shegan
    Luo, Suxia
    Guo, Baohong
    Li, Xionghui
    Su, Yangzhi
    Wang, Qian
    EUROPEAN JOURNAL OF CANCER, 2023, 178 : 1 - 12
  • [10] Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
    Meric-Bernstam, Funda
    Hamilton, Erika P.
    Beeram, Muralidhar
    Hanna, Diana L.
    El-Khoueiry, Anthony B.
    Kang, Yoon-Koo
    Lee, Keun Wook
    Lee, Jeeyun
    Rha, Sun Young
    Chaves, Jorge M.
    Oh, Do-Youn
    Goodwin, Rachel Anne
    Ajani, Jaffer A.
    Gray, Todd
    Woolery, Joseph
    Elimova, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345